Antimicrobial activity of tigecycline and comparative agents against clinical isolates of staphylococci and enterococci from ICUs and general hospital wards at three Swedish university hospitals

References

• Henwood CJ, Livermore DM, Johnson AP, James D, Gardiner A, et al. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000; 46: 931–40
   PubMed Web of Science ®Google Scholar
• Simonsen GS, Småbrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG, et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in 5 Nordic hospitals. J Antimicrob Chemother 2003; 51: 323–31
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Johnson BM, Hoban DJ, Johson JL, Dowzicky MJ, Wu DH, et al. Determining incidences of extended spectrum β-lactamases producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002. Int J Antimicrob Agents 2004; 24: 119–24
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19–36
   PubMed Web of Science ®Google Scholar
• Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycycline tigecycline (GAR-936) against 1924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400–4
   PubMed Web of Science ®Google Scholar
• Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC bacteraemia resistance surveillance programme. J Antimicrob Chemother 2004; 53: 1018–32
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203–8
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky DH, Wu DH, et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates, 2001–2002. Diagn Microbiol Infect Dis 2005; 51: 291–5
   PubMed Web of Science ®Google Scholar
• Olson MW, Ruzin A, Feyfant E, Rush TS, III, O'Connell JO, Bradford PA. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2156–66
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738–44
   PubMed Web of Science ®Google Scholar
• Swedish Reference Group for Antibiotics (SRGA) and its subcommittee on Methodology (SRGA-M). MIC breakpoints from SRGA, 2006 August 30 and 2006 December 22. [cited 2007 May 11]. Available from http://www.srga.org/MICTAB/MICTAB1.htlm and http://www.srga.org//MICTAB/MICTAB2.htlm.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing, EUCAST clinical MIC breakpoints, 2006 June 20. (cited 2007 May 11). Available from http://www.srga.org/eucastwt/MICTAB/index.htlm.
   Google Scholar
• Jonasson J, Olofsson M, Monstein HJ. Classification, identification and subtyping of bacteria based on pyrosequencing and signature matching of 16S rDNA fragments. APMIS 2002; 263: 263–72
   Google Scholar
• Bolmström A, Karlsson Å, Engelhardt A, Ho P, Petersen PJ, Bradford PA, et al. Validation and reproducibility assessment of tigecycline MIC determinations by E-test. J Clin Microbiol 2007; 45: 2474–9
   PubMed Web of Science ®Google Scholar
• Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005; 49: 3903–9
   PubMed Web of Science ®Google Scholar
• Claesson C, Hällgren A, Nilsson M, Svensson E, Hanberger H, Nilsson LE, et al. Susceptibility of staphylococci and enterococci to antimicrobial agents at different ward levels in 4 northern European countries. Scand J Infect Dis 2007; 39: 1002–12
   PubMed Web of Science ®Google Scholar
• European antimicrobial resistance surveillance systems. EARSS annual report 2006 (cited 2007 November 30). Available from http://www.rivm.nl/earss/Images/EARSS%20AR%202006%20final_tcm61-44176.pdf.
   Google Scholar
• Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50: 3479–84
   PubMed Web of Science ®Google Scholar
• Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant Gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Am J Infect Control 2007; 35: 521–6
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnridge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY program report (2003–2004). Int J Antimicrob Agents 2007; 30: 143–9
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr, Eliopoulos GM. Relationship of MIC and bacterial activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 2004; 42: 2398–402
   PubMed Web of Science ®Google Scholar
• Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995; 39: 1842–7
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis 2001; 32(Suppl 2)S114–32
   PubMed Web of Science ®Google Scholar
• Lim HS, Lee H, Roh KH, Yum JH, Yong D, Lee K, et al. Prevalence of inducible clindamycin resistance at a Korean tertiary care hospital. Yonsei Med J 2006; 47: 480–4
   PubMed Web of Science ®Google Scholar
• Pimentel JD, Lum GD. Use of the D-test to determine the prevalence of inducible clindamycin-resistant Staphylococcus aureus in a northern territory hospital. Pathology 2006; 38: 258–79
   PubMed Web of Science ®Google Scholar
• Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® annual appraisal of potency and spectrum study. Int J Antimicrob Agents 2007; 29: 295–301
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Jr, Archibald LK, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Clin Infect Dis 1999; 29: 245–52
   PubMed Web of Science ®Google Scholar
• Vaech LA, Pfaller MA, Barett M, Koontz FP, Wenzel RP. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990; 28: 2064–8
   PubMed Web of Science ®Google Scholar
• Bivasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 2000; 19: 403–17
   PubMed Web of Science ®Google Scholar
• Kronvall G, Karlsson I, Walder M, Sörberg M, Nilsson LE. Epidemiological MIC cut-off values for tigecycline calculated from E-test MIC values using normalized resistance interpretation. J Antimicrob Chemother 2006; 57: 498–505
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing, Clinical MIC breakpoints. Click on tigecycline. Antimicrobial wild-type distribution of microorganisms (cited 2007 November 30). Available from http://217.70.33.99/Eucast2/SearchController/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=345&Specium=-1.
   Google Scholar
• Hällgren A, Abednazari H, Ekdahl C, Hanberger H, Nilsson M, Samuelsson A, et al. Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems. J Antimicrob Chemother 2001; 48: 53–62
   PubMed Web of Science ®Google Scholar
• Hanberger H, Erlandsson M, Burman LG, Cars O, Gill H, Lindgren S, et al. High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Scand J Infect Dis 2004; 36: 24–30
   PubMed Web of Science ®Google Scholar
• Scouthen MA, Hoogkamp-Korstanje JAA, Meis JFG, Voss A and the European VRE study group. Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 2000;19:816–22.
   PubMed Web of Science ®Google Scholar
• Johnson AP, Warner M, Woodford N, Speller DCE, Livermore DM. Antibiotic resistance among enterococci causing endocarditis in the UK: analysis of isolates referred to a reference laboratory. Br Med J 1998; 137: 629–30
   Google Scholar
• Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000; 31: 586–9
   PubMed Web of Science ®Google Scholar